Worldwide study aims to uncover hidden patterns in hidradenitis suppurativa care
NCT ID NCT07659769
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This international study observes how people with hidradenitis suppurativa (a chronic skin condition) access healthcare, what treatments they receive, and how the disease affects their quality of life. Researchers collect data from routine medical records across multiple countries to identify differences in care and outcomes. The goal is to understand current treatment patterns and find ways to improve care for patients worldwide.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- This study could reveal gaps in care and help improve treatment strategies for people with hidradenitis suppurativa worldwide.
- What could go wrong
- As an observational study, it does not test a new treatment, so direct patient benefits are not guaranteed. Results depend on the quality of routine medical records.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 9,600 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient populations across world regions seen for hidradenitis suppurativa.
- Ages
-
14 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Signed General Consent Form, or equivalent document * Confirmed diagnosis of Hidradenitis Suppurativa Exclusion Criteria: * Inability to provide informed consent. * Datasets with ambiguous or unclear diagnosis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa (acne inversa) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Zurich
RECRUITINGZurich, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill aims to calm painful skin flares
- Can monthly selfies and symptom logs reveal how chronic skin diseases flare and settle?
- Can a Bladder-Derived patch improve wound healing in daily practice?
- Can a daily pill tame the painful lesions of hidradenitis suppurativa?
- Can a new injection quiet the painful lumps of hidradenitis suppurativa?
- Can a new injection tame the painful lumps of hidradenitis suppurativa?